Blog Exposure - Clearside Reports Encouraging Data from Phase-2 Trial of CLS-TA Used with Eylea in Patients with Diabetic Macular Edema
LONDON, UK / ACCESSWIRE / June 4, 2018 / If you want access to our free research report on Clearside Biomedical, Inc. (NASDAQ: CLSD) ("Clearside"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CLSD as the Company's latest news hit the wire. On May 31, 2018, the Company announced positive top-line results from its Phase-2 clinical trial, TYBEE, evaluating suprachoroidal CLS-TA used with intravitreally-administered EYLEA® (aflibercept) in patients with diabetic macular edema (DME) over a 6-month evaluation period. Register today and get access to over 1,000 Free Research Reports by joining our site below:
www.active-investors.com/registration-sg
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Clearside Biomedical most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
www.active-investors.com/registration-sg/?symbol=CLSD
Combination of Suprachoroidal CLS-TA with Intravitreal Eylea Met Primary and Secondary Endpoints in 6-Month Trial
TYBEE, which is a multicenter, randomized, masked, controlled Phase-2 trial, enrolled 71 patients who were naïve to treatment for DME. Patients were randomized 1:1 to receive either quarterly treatments of suprachoroidal CLS-TA together with intravitreal Eylea (the "combination arm"), or four monthly treatments of intravitreal Eylea plus a sham suprachoroidal procedure (the "control arm"), with patients in either arm receiving intravitreal Eylea treatment at months 4 and 5 as needed. The trial met its primary endpoint of mean improvement in best corrected visual acuity (BCVA) from baseline over six months, as measured using the Early Treatment of Diabetic Retinopathy Trial (ETDRS) scale. Patients in the combination arm gained an average of 12.3 ETDRS letters compared to 13.5 ETDRS letters in the Elyea alone control arm.
Administration of suprachoroidal CLS-TA together with intravitreal Eylea met a key secondary endpoint with a mean reduction from baseline of 208 microns in central subfield thickness (CST) of the retina at six months, compared to a 177 micron mean reduction in the control arm. Suprachoroidal CLS-TA, used together with intravitreal Eylea, was generally well tolerated, with no treatment-related serious adverse events reported in the TYBEE trial through the 24-week evaluation period.
Suprachoroidal CLS-TA when Given Together with an Anti-VEGF Agent has Potential to Provide a More Lasting Response to DME Treatment
Daniel White, President and Chief Executive Officer (CEO) of Clearside, stated that the Company is pleased with the top-line results of this Phase-2 trial, which signals the potential utility of suprachoroidal CLS-TA to improve on the existing standard of care in DME, another sight-threatening disease like RVO and uveitis. White added that, based on the TYBEE data, Clearside believes suprachoroidal CLS-TA, when given together with an anti-VEGF agent, has the potential to provide a more lasting response to treatment, thereby substantially lowering the treatment frequency and burden for DME patients.
Reports suggest that, post announcement of the news, the Company's shares slumped in pre-market trading.
Clearside to Share Detailed Results from TYBEE Trial at an Upcoming Medical Meeting
Clearside is continuing to analyze data from the TYBEE trial and detailed results will be shared at an upcoming medical meeting. Based on the initial results from this trial, the Company will begin evaluating a Phase-3 program to continue investigating the potential for its proprietary treatment approach in patients with diabetic eye disease.
About Diabetic Macular Edema (DME)
DME is an accumulation of fluid in the macula, which is a part of the retina that controls most detailed vision abilities, due to leaking blood vessels. In order to develop DME, one must first have diabetic retinopathy. Diabetic retinopathy is a disease that damages the blood vessels in the retina, resulting in vision impairment. Left untreated, these blood vessels begin to build up pressure in the eye and leak fluid, causing DME.
About Suprachoroidal CLS-TA
Suprachoroidal CLS-TA, which is Clearside's first investigational treatment, is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the back of the eye via the suprachoroidal space, or SCSTM, which is the space located between the choroid and the outer protective layer of the eye known as the sclera. CLS-TA specifically reduces inflammation and other complications that lead to the swelling of the macula, which is a leading cause of visual impairment and blindness. Clearside's proprietary suprachoroidal treatment approach is designed to enable the rapid dispersion of a high amount of medicine to the back of the eye so that an adequate amount of medicine reaches and stays at the site of disease and has the potential to act longer.
About Clearside Biomedical, Inc.
Founded in 2012 and headquartered in Alpharetta, Georgia, Clearside is a biopharmaceutical organization dedicated to developing treatments that restore and preserve vision for people with serious eye diseases. Clearside's proprietary suprachoroidal treatment approach offers an unprecedented access to the back of the eye where sight threatening diseases often occur.
Stock Performance Snapshot
June 01, 2018 - At Friday's closing bell, Clearside Biomedical's stock declined 1.12%, ending the trading session at $9.75.
Volume traded for the day: 1.04 million shares.
Stock performance in the three-month – up 24.68%; previous six-month period – up 37.52%; past twelve-month period – up 36.17%; and year-to-date - up 39.29%
After last Friday's close, Clearside Biomedical's market cap was at $315.02 million.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 1.0% at the end of the session.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
